P2Y 12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP

Platelets

Volumn 22, Issue 7, 2011, Pages 504-515

  Iyú, David ^a   Glenn, Jackie R ^a   White, Ann E ^a   Fox, Sue C ^a   Dovlatova, Natalia ^a   Heptinstall, Stan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

DG 041; EP3 receptor; P2Y 12 antagonists; Platelets; Prostaglandins

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CYCLIC AMP; DG 041; FORSKOLIN; ILOPROST; PRASUGREL ACTIVE METABOLITE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICAGRELOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE PHOSPHATE; CELL ADHESION MOLECULE; DRUG DERIVATIVE; PHOSPHOPROTEIN; PROSTAGLANDIN E; PROSTAGLANDIN E RECEPTOR 3; PTGER3 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; IC 50; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; DRUG ANTAGONISM; METABOLISM; THROMBOCYTE;

ADENOSINE MONOPHOSPHATE; ASPIRIN; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYCLIC AMP; HUMANS; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDINS E; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PURINERGIC P2Y12;

EID: 80052214031     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.576284     Document Type: Article

References (41)

1. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005;31:174-83.
2. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:357-374.
3. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896.
4. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-1295.
5. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008;19:125-133.
6. Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;21:195-204.
7. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist ARC69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85:401-407.
8. Husted S, van Giezen JJ. Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009;27:259-274.
9. Van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to P2Y12 receptors independently from ADP but antagonizes ADP-induced receptor signalling and platelet aggregation. J Thromb Haemost 2009;7:1556-1565.
10. Cattaneo M. New P2Y12 inhibitors. Circulation 2010; 121:171-179.
11. Storey RF, Sanderson HM, May JA, White AE, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110:925-934.
12. Dorsam RT, Kunapuli S. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340-344.
13. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-472.
14. Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, et al. DG-041 inhibits the EP3 prostanoid receptor - A new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008;19: 605-613.
15. Singh J, Zeller W, Zhou N, Hategen G, Mishra R, Polozov A, Yu P, Onua E, Zhang J, Zembower D, et al. Identification of DG-041, a potent and selective prostanoid EP3 receptor antagonist, as a novel anti-platelet agent. ACS Chem Biol 2009;4:115-126.
16. Fabre JE, Gurney ME. Limitations of current therapies to prevent thrombosis: A need for novel strategies. Mol Bio Syst 2010;6:305-315.
17. Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, et al. Structure-activity relationship studies leading to the identification of (2E)-3-l-(2,4-dichlorophenyl)methyl-5-fluoro-3- methyl-lH-indol-7-yl-N-(4,5-dichloro-2-thienyl)sulfonyl-2- propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem 2010;53:18-36.
18. Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996;72:171-191.
19. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties and functions. Physiol Rev 1999;79:193-226.
20. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal 2007;7:1359-1374.
21. Cooper JA, Hill SJ, Alexander SPH, Rubin PC, Horn EH. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. Br J Clin Pharmacol 1995;40:43-50.
22. Amisten S, Braun OÖ; , Bengtsson A, Erlinge D. Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008;122:47-57.
23. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. A new role for the A2b adenosine receptor regulating platelet function. J Throm Haemost 2010;8:817-827.
24. Seamon KB, Daly JW. Activation of adenylate cyclase by the diterpene forskolin does not require the guanine nucleotide regulatory protein. J Biol Chem 1981;256:97-99.
25. IyÚ D, Jüttner M, Glenn JR, White AE, Johnson AJ, Fox SC, Heptinstall S. PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 2010;94:9-16.
26. Smith JP, Haddad EV, Downey JD, Breyer RM, Boutaud O. PGE2 decreases reactivity of human platelets by activating EP2 and EP4. Thromb Res 2010;126:23-29.
27. IyÚ D, Glenn JR, White AE, Johnson A, Fox SC, Heptinstall S. The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function. Platelets 2010;21:329-342.
28. IyÚ D, Glenn JR, White AE, Fox SC, van Giezen H, Nylander S, Heptinstall S. Mode of action of P2Y12 antagonists as inhibitors of platelet function. Thromb Haemost 2011;105:96-106.
29. IyÚ D, Glenn JR, White AE, Fox SC, Heptinstall S. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler Thromb Vasc Biol 2010;31:416-422.
30. Fox SC, Behan MWH, Heptinstall S. Inhibition of ADPinduced intracellular Ca2ρ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004;35:39-46.
31. Cattaneo M, Lecchi A. Inhibition of P2Y12 receptor by adenosine diphosphate potentiates the antiplatelet effects of prostacyclin. J Thromb Haemost 2007;5:577-582.
32. Kuriyama S, Kashiwagi H, Yuhki KI, Kojima F, Yamada T, Fujino T, Hara A, Takayama K, Maruyama T, Yoshida A, et al. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 2010;104:796-803.
33. Philipose S, Konya V, Sreckovic I, Marsche G, Lippe IT, Peskar BA, Heinemann A, Schuligoi R. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2010;30:2416-2423.
34. Klabunde RE. Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983;93:21-26.
35. Dawicki DD, Agarwal KC, Parks RE. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 1985;34:3965-3972.
36. Gamboa A, Abraham R, Diedrich A, Shibao C, Paranjape SY, Farley G, Biaggioni I. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke 2005;36:2170-2175.
37. Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease and the vasculature. Vascular Pharmacol 2008; 48:143-149.
38. Lee K, Kim JY, Yoo BS, Yoon J, Hong MK, Ahn MS, Choe H, Lee SH. Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. J Thromb Haemost 2010;8:2578-2579.
39. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
40. Nainggolan L, Miller R. 17 December (2010). No US approval for ticagrelor yet; FDA requests further analysys of PLATO. The heart.org. 5http://www.theheart.org/article/ 1164221.do?utm-campaign=newsletter&utm- medium=.email&utm-source=(2010)1217-breakingNews4 Accessed (2010) Dec 20.
41. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2010; 55:1671-1678.